For patients with recent-onset, moderate-to-severe RA1

In PREMIER, improved clinical response with HUMIRA + MTX vs MTX alone was demonstrated by significant improvement in ACR scores at 2 years1

~2x as many HUMIRA + MTX patients achieved ACR70 and 90 vs MTX alone1

Premier: ACR70 and 90 Response Rates

The above analysis is of the intent-to-treat study population using nonresponder imputation methodology. Patients who withdrew or had missing values were considered nonresponders.

59% of HUMIRA + MTX patients achieved ACR50 at 2 years vs 43% with MTX alone (P<0.001)1,2
62% of HUMIRA + MTX patients achieved ACR50 at 1 year vs 46% with MTX alone (P<0.001)1,2

Clinical remission measure (DAS28<2.6) was demonstrated by a significantly greater number of patients treated with HUMIRA + MTX vs MTX alone at 2 years1

~1 out of 2 patients achieved clinical remission measure (DAS28<2.6)1

Premier: Clinical Remission Measure

^†

Disease Activity Score 28 (DAS28) is a composite index that includes variables such as the number of tender and swollen joints, erythrocyte sedimentation rate (ESR), or CRP, and may include the patient’s assessment of disease activity.3-5

DAS28<2.6 was achieved by 43% of HUMIRA + MTX patients vs 21% of MTX-alone patients at 1 year (P<0.001)1

06G-64C-Q352-6

HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. HUMIRA can be used alone or in combination with methotrexate. HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in adult patients with psoriatic arthritis. HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please see Important Safety Information. Serious and sometimes fatal side effects have been reported with HUMIRA, including tuberculosis and other serious infections.

Please see full prescribing information.

References: 1. Breedveld FC, Weisman MH, Kavanaugh AF, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. 2. HUMIRA full prescribing information. 3. van Gestel AM, Prevoo MLL, van ’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: .comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39:34-40. 4. van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-1850. 5. Prevoo MLL, van ’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48.

Legal Notices/Privacy Policy. Copyright 2007, Abbott Laboratories, Abbott Park, Illinois, U.S.A. If you have any questions about Abbott's HUMIRA.com Web site that have not been answered click here. This Web site and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.